TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP cut its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 45.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 164,431 shares of the company's stock after selling 139,337 shares during the period. Wellington Management Group LLP owned about 0.49% of TransMedics Group worth $10,252,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of TMDX. Clear Creek Financial Management LLC bought a new position in shares of TransMedics Group in the 4th quarter worth $352,000. Vaughan Nelson Investment Management L.P. raised its position in shares of TransMedics Group by 9.9% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock worth $22,547,000 after acquiring an additional 32,605 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of TransMedics Group by 14.9% in the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after acquiring an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new position in shares of TransMedics Group in the 4th quarter worth $6,734,000. Finally, Peregrine Capital Management LLC raised its position in shares of TransMedics Group by 64.0% in the 4th quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock worth $4,124,000 after acquiring an additional 25,814 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the sale, the director now owns 732 shares in the company, valued at $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Weill sold 732 shares of the company's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the sale, the director now owns 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,732 shares of company stock worth $1,416,710. 7.00% of the stock is currently owned by insiders.

TransMedics Group Stock Performance

TransMedics Group stock traded up $1.07 during trading hours on Wednesday, hitting $129.81. 789,937 shares of the stock traded hands, compared to its average volume of 1,355,534. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm's 50 day moving average price is $97.54 and its 200-day moving average price is $79.14. The stock has a market capitalization of $4.39 billion, a price-to-earnings ratio of 138.10 and a beta of 2.10. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.35 EPS. As a group, equities analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on TMDX. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer boosted their price target on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Finally, Piper Sandler reissued an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $128.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.